Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand Pharma's obesity drug candidate.

Roche acquired rights to an obesity therapy by Danish biotech firm Zealand Pharma in a collaboration deal worth up to $5.3 billion, as the Swiss pharmaceutical company seeks to boost its prospects in ...

Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to co-develop a weight-loss treatment.

Have a wonderful day and please do stay in touch… Looking to expand its obesity offerings, Roche has partnered with Zealand Pharma to license an experimental weight loss drug for $1.65 billion ...

Roche is expanding its scope to a promising but competitive new obesity target, committing $1.65 billion up front to partner on a clinical-stage Zealand Pharma molecule with the potential to be a ...

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

(RTTNews) - Zealand Pharma A/S (ZEAL) announced a global collaboration and license agreement with Roche (RHHBY) to develop petrelintide, Zealand Pharma's amylin analog. The two companies will co ...

Zealand Pharma will receive up to $5.3 billion under its obesity drug partnership with Roche. Roche and Zealand Pharma will co-commercialize petrelintide in the U.S. and Europe, sharing profits 50/50.

For more on Immunovant’s new data, go here; for more on Sarepta’s gene therapy, go here; to learn more about Zealand’s deal ...

Investing.com -- Zealand Pharma shares surged more than 41% on Wednesday after announcing a $5.3 billion licensing deal with Roche for its GLP-1 obesity therapy petrelintide. The agreement gives ...

ZURICH, March 12 (Reuters) - Roche (ROG.S), opens new tab has acquired rights to an obesity therapy by Denmark's Zealand Pharma (ZELA.CO), opens new tab in a collaboration deal worth up to $5.3 ...

ZURICH (Reuters) -Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, as the Swiss drugmaker seeks to boost its prospects ...